Bioelectric medicine market seen reaching $39.19 billion by 2030

The Business Research Company projects the bioelectric medicine market will grow from $26.81 billion in 2025 to $39.19 billion by 2030, driven by rising healthcare spending, neuromodulation advances and broader use of device-based therapies. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - The bioelectric medicine market is set for sustained growth as health systems invest more in device-based treatments for neurological, cardiovascular and chronic conditions. - Rising healthcare spending, expanding neuromodulation use and stronger demand for minimally invasive care are supporting longer-term adoption. - The trend could accelerate development of electroceuticals and other therapies that use electrical impulses instead of, or alongside, drugs.

What happened: - The Business Research Company released a trends and forecast analysis of the global bioelectric medicine market on Nov. 5, 2026. - The market is projected to rise from $26.81 billion in 2025 to $29.2 billion in 2026. - The report forecasts the market will reach $39.19 billion by 2030. - The company said the market grew on the back of more neurological disorders, wider use of cardiac rhythm management devices and progress in neuromodulation technology.

The details: - The report says the market’s 2025-2026 growth reflects a compound annual growth rate of 8.9%. - The 2026-2030 outlook implies a 7.6% CAGR. - Future growth is tied to demand for personalized medicine, broader access to minimally invasive procedures, more electroceutical research funding, greater use of digital health tools and stronger focus on chronic disease management. - Healthcare spending is a key market driver because higher outlays support research, development and adoption of bioelectric therapies. - The UK Office for National Statistics reported in May 2024 that healthcare expenditure in 2023 reached about $382.5 billion, up from $370.7 billion in 2022. - The report says acceptance of implantable and non-invasive device-based therapies is expanding because they can more precisely modulate nerve activity. - The report includes coverage of Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The company also promoted a free sample of the report: Download the sample report. - The full report is available here: View the full market report.

Between the lines: - North America held the largest share of the market in 2025, signaling stronger current adoption and more established healthcare infrastructure. - Asia-Pacific is expected to be the fastest-growing region over the forecast period, pointing to rising healthcare investment, higher patient awareness and infrastructure buildout. - The report’s added analytics features suggest vendors are positioning buyers to use the data for market sizing, technology tracking and competitive benchmarking.

What's next: - The market’s next phase will likely hinge on whether healthcare systems keep increasing spending on advanced devices and chronic care management. - Adoption could rise further if neuromodulation devices and other bioelectric therapies continue to improve on safety, precision and ease of use. - The report says 2026 editions include updated graphics, tables, TAM analysis, company scoring matrices, forecasting dashboards and trend analysis tools.